Premium
Advances in laboratory testing for thrombophilia
Author(s) -
Johnson Nicholas V.,
Khor Bernard,
Van Cott Elizabeth M.
Publication year - 2012
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23186
Subject(s) - bivalirudin , argatroban , activated protein c resistance , antithrombin , thrombophilia , prothrombin g20210a , factor v leiden , medicine , rivaroxaban , discovery and development of direct thrombin inhibitors , protein c , dabigatran , direct thrombin inhibitor , lupus anticoagulant , protein s , hirudin , thrombin , warfarin , heparin , thrombosis , venous thrombosis , atrial fibrillation , platelet , percutaneous coronary intervention , myocardial infarction
Testing for hereditary thrombophilia typically includes tests for activated protein C resistance (APC‐R) and/or factor V Leiden, protein C, protein S, antithrombin, and prothrombin G20210A. New options for these assays have become available in recent years, with different advantages and disadvantages among the currently available methods. Potential interferences for each assay type are discussed, including lupus anticoagulants, heparin, warfarin, direct thrombin inhibitors (such as argatroban, dabigatran, hirudin, or bivalirudin), rivaroxaban, factor deficiencies or elevations, factor V Leiden, and specific mutations that the assay(s) might not be able to detect. Causes of acquired deficiencies are also described, as these must be carefully excluded before diagnosing a hereditary deficiency of protein C, protein S, or antithrombin. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.